Fundz

Tempest Therapeutics Appoints John Frederick as Class III Director

PUBLIC · TPSTOct 19, 2026

Position

Director

Company

Tempest Therapeutics

John Frederick
BrisbaneBiotechnologyHealthcareHealth CareTherapeuticsBiopharma

Description

Tempest Therapeutics, Inc. has appointed Mr. John Frederick to serve as a Class III director of its Board

Quick answer

Tempest Therapeutics Appoints John Frederick as Class III Director (October 19, 2026). Tempest Therapeutics is based in Brisbane, California, United States.

Who is the new Director at Tempest Therapeutics?
Tempest Therapeutics named John Frederick Director, announced October 19, 2026.
What did Tempest Therapeutics announce on October 19, 2026?
Tempest Therapeutics, Inc. has appointed Mr. John Frederick to serve as a Class III director of its Board
What does Tempest Therapeutics do?
Tempest Therapeutics is a development-stage biotechnology company.
Where is Tempest Therapeutics based?
Tempest Therapeutics is based in Brisbane, California, United States.
Which similar companies made leadership changes around the same time?
Gyre Therapeutics (October 22, 2026), Retension Pharmaceuticals (October 23, 2026), Verastem Oncology (October 14, 2026) and AbbVie Inc. (November 2, 2026) also announced leadership changes within 45 days of Tempest Therapeutics.

Source: Fundz verified event record.

Other recent leadership changes in Healthcare and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Tempest Therapeutics, and when

A new leader at Tempest Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Tempest Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Tempest Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Tempest Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Tempest Therapeutics

Location

2000 Sierra Point Parkway

Brisbane, California, United States

About

Tempest Therapeutics is a development-stage biotechnology company.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Tempest Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Stephen
Senior decision-maker at this company
••••••••@••••••••

See Stephen's verified email →

Justin
Likely contact at this company
••••••••@••••••••

See Justin's verified email →

Matt
Senior decision-maker at this company
••••••••@••••••••

See Matt's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Tempest Therapeutics's next move

Learn about Strategic plan

Tempest Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.